Physician profile
Kevin Davis
NPI 1811903529
$1,159.36
in general payments reported to CMS, 2019-2025
18 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $80.06 · 2023: $111 · 2024: $105 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $193.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.89 | 2021-2023 | Farxiga |
| Vanda Pharmaceuticals INC. | $149.11 | 2025 | Hetlioz, Fanapt |
| Grifols USA, LLC | $101.75 | 2024-2025 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.87 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $88.38 | 2021-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.42 | 2025 | Caplyta |
| Pfizer INC. | $56.47 | 2021 | |
| Glaxosmithkline, LLC. | $42.47 | 2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Novo Nordisk INC | $40.52 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $33.22 | 2021-2022 | |
| Dexcom, INC. | $26.52 | 2025 | Dexcom G6 Transmitter |
| Indivior INC. | $24.66 | 2024 | Sublocade |
| Alkermes, INC. | $21.84 | 2025 | Aristada, Lybalvi |
| Abbott Laboratories | $18.12 | 2025 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.37 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $15.16 | 2021 | |
| Genentech USA, INC. | $3.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.